AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32098573
Drug: Fluoropyrimidine-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoropyrimidine-based neoadjuvant chemotherapy (NACT) administered to 45 patients for a median of 8 weeks prior to surgical resection.
Trial: 33940235
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg kg−1 of low dose rocuronium
Trial: 32384953
Drug: nAg‐NPs (≥0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nAg‐NPs (≥0.5 g/mL)
Trial: 32384953
Drug: nAg‐NPs (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nAg‐NPs (0.05 g/mL)
Trial: 32384953
Drug: nAg‐NPs (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nAg‐NPs (5 g/mL)
Trial: 32979978
Drug: Gabapentin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (titrated to a maximum dose of 2700 mg daily)
Trial: 35697547
Drug: Intraoperative lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative lidocaine infusion (continuous infusion of 2 mg kg‐1 h‐1 after 1.5 mg kg‐1 bolus at induction of anaesthesia)
Trial: 32385495
Drug: Active reference
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active reference treatment (not specified)
Trial: 32917288
Drug: Mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extract (0.01 to 20 mg subcutaneously three times per week for 9 months)
Trial: 33109233
Drug: Neo-adjuvant lapatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant lapatinib, trastuzumab, or their combination plus paclitaxel
Trial: 39369249
Drug: Intravenous induction
RxNorm normalized name: Intravenous induction agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous induction
Trial: 36047598
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous ferric carboxymaltose
Trial: 36047598
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous ferric carboxymaltose
Trial: 32334548
Drug: mDCF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDCF plus atezolizumab (800 mg every 2 weeks)
Trial: 33129363
Drug: Favipiravir and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir and Hydroxychloroquine combination
Trial: 34610151
Drug: Adjunctive Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Er:YAG laser (ERL) in non-surgical periodontal therapy (NSPT)
Trial: 34610151
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment in non-surgical periodontal therapy (NSPT)
Trial: 33496530
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy at baseline
Trial: 34836152
Drug: Common Bean
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Bean Baked Snack (CBBS) consumption (32 g for four weeks)
Trial: 36089442
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of force
Trial: 36089442
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g of force
Trial: 36089442
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g or 150 g of force
Trial: 35405603
Drug: Probiotic kefir
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic kefir (180 mL/d)
Trial: 32621587
Drug: Hydrocortisone treatment
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone treatment regimens (three or four times daily)
Trial: 34269632
Drug: Interventions designed
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions designed to enhance treatment engagement
Trial: 35080497
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (8 weeks of placebo treatment unrelated to PA and FVC)
Trial: 32159187
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch enriched cookies (16 g of RS per day)
Trial: 34813821
Drug: Traditional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional training (TRAD-G)
Trial: 36297014
Drug: BCAAs (0.17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAAs (0.17 g/kg BCAAs + 0.17 g/kg glucose)
Trial: 36297014
Drug: Placebo (0.34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.34 g/kg glucose)
Trial: 34447267
Drug: Celecoxib oral
RxNorm normalized name: celecoxib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib oral solution (120 mg, 4.8 mL)
Trial: 35671039
Drug: Efpeglenatide 2
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 2 mg
Trial: 35671039
Drug: Efpeglenatide 4
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 4 mg
Trial: 35671039
Drug: Efpeglenatide 6
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 6 mg
Trial: 32891292
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy integrated with family recollection (15 minutes, twice a day for 6 days)
Trial: 33265920
Drug: Acyclovir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (750 mg/m2 intravenously)
Trial: 33265920
Drug: Acyclovir (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (1600 mg per day orally)
Trial: 33265920
Drug: Acyclovir (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (250 mg/m2 per day intravenously)
Trial: 36115256
Drug: Somatostatin analogue
RxNorm normalized name: Somatostatin analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analogue therapy (SSA)
Trial: 35015806
Drug: High-protein yogurt
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein yogurt (10 g protein/100 g)
Trial: 35015806
Drug: Normal-protein yogurt
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein yogurt (3.5 g protein/100 g)
Trial: 33368338
Drug: High-dose valaciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valaciclovir (900 mg, three times daily for 10 days)
Trial: 33368338
Drug: Low-dose valaciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valaciclovir (300 mg, two times daily for 10 days)
Trial: 33368338
Drug: High-dose valaciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valaciclovir
Trial: 32419473
Drug: Lenvatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib treatment for patients weighing <60 kg
Trial: 32419473
Drug: Lenvatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib treatment for patients weighing ≥60 kg
Trial: 35212278
Drug: Zuo acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuo acupuncture treatment plus lifestyle interventions
Trial: 33486596
Drug: Reduced 2016‐AAO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced 2016‐AAO dose (2–3 mg/kg/day)
Trial: 33486596
Drug: Full 2016‐AAO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full 2016‐AAO dose (5 mg/kg/day)
Trial: 33653121
Drug: Midazolam (0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.045 mg/kg over 40 minutes)
Trial: 34060462
Drug: Three-day post-operative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day post-operative course of oral antibiotics
Trial: 34060462
Drug: Three-day post-operative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day post-operative course of intravenous antibiotics
Trial: 35063943
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with frontline carboplatin and paclitaxel chemotherapy
Trial: 32979860
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid cream
Trial: 34143258
Drug: LV‐RBP (52.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV‐RBP (52.5 g of PMF104 in 500 mL of water)
Trial: 34143258
Drug: FV‐RBP (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FV‐RBP (105 g of PMF104 in 1000 mL of water)
Trial: 32423422
Drug: Local solutions
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local solutions implemented to strengthen LTBI management
Trial: 33593307
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT) specialist consultation
Trial: 33782959
Drug: TA (4
RxNorm normalized name: Triamcinolone acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TA (4 mg/mL) intradermal injections every 2 weeks
Trial: 33782959
Drug: TA (10
RxNorm normalized name: {56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA (10 mg/mL) intradermal injections every 2 weeks
Trial: 33782959
Drug: Topical TA
RxNorm normalized name: Doak 2% Topical Tar Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TA cream (10% concentration) twice daily
Trial: 32176175
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy and observation
Trial: 36763358
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg
Trial: 32790904
Drug: Vortioxetine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (15 mg/daily)
Trial: 32790904
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/daily)
Trial: 32790904
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/daily)
Trial: 32790904
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg/daily)
Trial: 32790904
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg/daily)
Trial: 34006069
Drug: Guided bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided bone regeneration with titanium‐reinforced polytetrafluoroethylene membrane and simultaneous implant placement (Group A)
Trial: 34006069
Drug: Guided bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided bone regeneration with titanium mesh and collagen membrane and simultaneous implant placement (Group B)
Trial: 34534293
Drug: Maternal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vitamin D sufficiency (25(OH)D ≥ 30 ng/ml) in the third trimester
Trial: 34958861
Drug: 6'-Sialyllactose (6'-SL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6'-Sialyllactose (6'-SL), 3 g powder orally administered twice a day for 12 weeks
Trial: 34958861
Drug: Placebo (maltodextrin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin), 3 g powder orally administered twice a day for 12 weeks
Trial: 33755835
Drug: Serum CYR61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CYR61 ≥ 236.2 pg/mL
Trial: 33713473
Drug: Trapezius muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapezius muscle injection (TMI) with 5 mL of 0.25% bupivacaine two times, with a 1-week interval
Trial: 33713473
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 20 mL of 0.125% bupivacaine in the second week after TMI
Trial: 33713473
Drug: Repeated TMI
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated TMI (two injections)
Trial: 32205201
Drug: PA2 -
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PA2 - 2 wt% proanthocyanidins solution applied for 60s
Trial: 32205201
Drug: PA5 -
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PA5 - 5 wt% proanthocyanidins solution applied for 60s
Trial: 34648685
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg PO daily)
Trial: 34648685
Drug: Finasteride (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (2.5 mg PO daily) in combination with topical clindamycin 2% solution
Trial: 36013498
Drug: Topical instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical instillation of 0.3% ofloxacin, 4 drops at 15 min intervals before surgery
Trial: 35178811
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg once a day)
Trial: 32375754
Drug: iCBT (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-based cognitive-behavioral therapy) intervention for PTSD, 5 weeks duration, 10 writing assignments (twice a week)
Trial: 32375754
Drug: iCBT (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-based cognitive-behavioral therapy) intervention for PTSD
Trial: 35018508
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg three times a day
Trial: 34327833
Drug: Topical monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical monotherapy
Trial: 34327833
Drug: Intensive approach
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive approach using drugs from three different classes plus 360° laser trabeculoplasty
Trial: 32415720
Drug: CNTO 7160
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 7160 (3 mg/kg) in patients with AD
Trial: 32415720
Drug: CNTO 7160
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 7160 (3 or 10 mg/kg) in patients with asthma or AD
Trial: 32415720
Drug: CNTO 7160
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 7160 (1-10 mg/kg)
Trial: 32415720
Drug: CNTO 7160
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 7160 (1 mg/kg IV every 2 weeks)
Trial: 36071623
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=27) received four one-hour low back pain-related education sessions in addition to eight 45-minute standard physical therapy sessions over 4 weeks.
Trial: 33694311
Drug: Lisinopril (ACEi)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (ACEi)
Trial: 32072592
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (specific intervention not detailed)
Trial: 36049646
Drug: RLRL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL therapy (100% power)
Trial: 35718656
Drug: tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tedizolid phosphate 200 mg once daily for 7 days
Trial: 35034050
Drug: Demographic characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic characteristics (younger, college education, single, employed, Han ethnicity, diagnosed with HIV in the past 6 years, not on antiretroviral therapy)
Trial: 33758387
Drug: Myo-inositol treatment
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol treatment
Trial: 33113596
Drug: Riluzole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (100 mg/d for 8 weeks)
Trial: 35272400
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride injection, 1 mg/kg intravenously.
Trial: 32518394
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.15% ophthalmic solution
Trial: 33234158
Drug: Ivermectin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Trial: 33234158
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Trial: 32281579
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g AZD0585
Trial: 32281579
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g AZD0585
Trial: 35718790
Drug: Maltodextrin and
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin and fructose beverage (800 mL at 10 hours and 400 mL at 2 hours before surgery)
Trial: 33409924
Drug: No zinc
RxNorm normalized name: ZINC OXIDE 140 mg in 1 mL TOPICAL CREAM [Lucin Organics Tinted Sunscreen SPF 30 Non Nano Zinc Oxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No zinc therapy (Control)
Trial: 36118673
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg daily) plus original oral hypoglycemic agents
Trial: 36118673
Drug: Original oral
RxNorm normalized name: Sucrets Original Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original oral hypoglycemic agents alone (control group)
Trial: 35908254
Drug: Masupirdine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masupirdine treatment
Trial: 33597439
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered at the same frequency as the vitamin A supplementation)
Trial: 35150610
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (250-300 mL of high anti-SARS-CoV-2 IgG titres methylene blue-treated convalescent plasma)
Trial: 35150610
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mL of sterile 0.9% saline solution)
Trial: 36342143
Drug: Baxdrostat 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 0.5 mg
Trial: 36266539
Drug: Baxdrostat 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 1.5 mg
Trial: 36266539
Drug: Baxdrostat 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 2.5 mg
Trial: 36266539
Drug: Baxdrostat 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 5.0 mg
Trial: 32201109
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB) patch 5 mcg applied at the end of surgery
Trial: 32201109
Drug: Conventional analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesics (combination of paracetamol and tramadol)
Trial: 33749571
Drug: Thiamine 1.5
RxNorm normalized name: thiamine 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 1.5 mg/kg
Trial: 32149954
Drug: Ingenol Mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol Mebutate Gel 0.05%
Trial: 32149954
Drug: Podophyllin Solution
RxNorm normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllin Solution 25%
Trial: 35114980
Drug: Ward-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ward-based intervention plus treatment as usual
Trial: 32553436
Drug: Cocktail therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail therapy (20 mL of 0.75% ropivacaine, 5 mg of morphine, 0.3 mg of epinephrine, 2 mg of betamethasone, saline solution to a total of 42 mL)
Trial: 32553436
Drug: Cocktail therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail therapy